Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction

Molecular and Cellular Biochemistry

Volumn 247, Issue 1-2, 2003, Pages 223-227

  Dhillon, Bikramjit ^a   Badiwala, Mitesh V ^a   Maitland, Andrew ^b   Rao, Vivek ^a   Li, Shu Hong ^a   Verma, Subodh ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Endothelial dysfunction; Homocysteine; Nitric oxide; Superoxide; Tetrahydrobiopterin

Indexed keywords

ACETYLCHOLINE; CALCIMYCIN; HOMOCYSTEINE; LUCIGENIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUPEROXIDE; TETRAHYDROBIOPTERIN;

ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; CELL STIMULATION; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG TARGETING; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HUMAN; HUMAN TISSUE; HYPERHOMOCYSTEINEMIA; INCUBATION TIME; MALE; NONHUMAN; RAT; RISK FACTOR; UMBILICAL VEIN; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; BIOPTERIN; CALCIMYCIN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; SUPEROXIDES; VASODILATOR AGENTS;

ANIMALIA;

EID: 0037743396     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024146501743     Document Type: Article

References (23)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 274: 1049-1057, 1995
2. Graham IM, Daly L, Refsum H, Robinson K, Brattstrom L, Ueland PM: Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. J Am Med Assoc 277: 1775-1781, 1997
3. Refsum H, Ueland P, Nygard O, Vollset S: Homocysteine and cardiovascular disease. Annu Rev Med 49: 31-62, 1998
4. Brattstrom L, Wilcken DE: Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 72: 315-323, 2000
5. Bellamy MF, McDowell IFW: Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 20: 307-315, 1997
6. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS: Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96: 2542-2544, 1997
7. Lang D, Kredan MB, Moat SJ, Hussain SA, Powell CA, Bellamy MF, Powers HJ, Lewis MJ: Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta - role of superoxide anions. Arterioscler Thromb Vasc Biol 20: 422-427, 2000
8. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky M: Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 279: F671-F678, 2000
9. Cosentino F, Luscher TF: Tetrahydrobiopterin and endothelial function. Cardiovasc Res 43: 274-278, 1999
10. Cosentino F, Luscher TF: Tetrahydrobiopterin and endothelial function. Eur Heart J 19(suppl G): G3-G8, 1998
11. Stuher DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF: Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: An FAD and FMN-containing flavoprotein. Proc Natl Acad Sci USA 88: 7773-7777, 1991
12. ++/calmodulin dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 281: 627-630, 1993
13. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM: Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 267: 24173-24176, 1992
14. Archer S: Measurement of nitric oxide in biological models. FASEB J 7: 349-360, 1993
15. Schmidt MM: Determination of nitric oxide via measurement of nitrite and nitrate in culture media. Biochemica 2: 22, 1995
16. Cosentino F, Barker JE, Brand MP, Heales SJ, Werner ER, Tippins JR, West N, Channon KM, Vople M, Luscher TF: Reactive oxygen species mediate endothelium-dependent relaxations in Tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol 21: 496-502, 2001
17. Tsutsui M, Milstien S, Katusic ZS: Effects of tetrahydriobiopterin on endothelial function in canine middle cerebral arteries. Circ Res 79: 336-342, 1996
18. Higman DJ, Strachan AMJ, Buttery L, Hicks RCJ, Springall DR, Greenhalgh RM et al.: Smoking impairs the activity of endothelial nitric oxide synthase in saphenous veins. J Thorac Cardiovasc Surg 16: 546-552, 1996
19. Verma S, Lovren F, Dumont AS, Mather K, Maitland A, Kieser TM, Triggle CR, Anderson TJ: Tetrahydrobiopterin improves endothelial function in human saphenous veins. J Thorac Cardiovasc Surg 120: 668-671, 2000
20. Verma S, Maitland A, Weisel RD, Li SH, Fedak PW, Pomroy NC, Mickle DA, Li RK, Ko L, Rao V: Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: Reversal with endothelin antagonism. J Thorac Cardiovasc Surg 123: 1120-1124, 2002
21. Verma S, Dumont AS, Maitland A: Tetrahydrobiopterin attenuates cholesterol induced coronary hyperreactivity to endothelin. Heart 86: 706-708, 2001
22. Schmid RA, Hillinger S, Walter R, Zollinger A, Stammberger U, Speich R, Schaffner A, Weder W, Schoedon G: The nitric oxide synathase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplanation. J Thorac Cardiovasc Surg 118: 726-732, 1999
23. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, Munzel T: Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers. Evidence for a dysfunction nitric oxide synthase. Circ Res 86: e36-e41, 2000